Sunday, March 26, 2023 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Derivative

PHILADELPHIA - Hemispherix Biopharma handed out big bonuses to its top dogs despite their misrepresentation of trials of its Ampligen drug, which ended so badly it knocked 43% off the share price in one day, shareholders say in a derivative complaint in state court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.